The role of cytochrome P450 in tumour development and progression and its potential in therapy

Journal of Pathology

Volumn 192, Issue 4, 2000, Pages 419-426

  Murray, Graeme I ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Breast cancer; Colon cancer; Cytochrome P450; Immunohistochemistry; Liver; Tumour

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450; CYTOCHROME P450 1B1; GENE PRODUCT; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; CANCER; CANCER RISK; CARCINOGENESIS; DNA POLYMORPHISM; GENE OVEREXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; XENOBIOTIC METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; NEOPLASMS; RATS;

EID: 0033668698     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH750>3.0.CO;2-0     Document Type: Review

References (67)

1. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature
2. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins
3. The human hepatic cytochromes P450 involved in drug metabolism
4. Microsomal cytochrome P450 and eicosanoid metabolism
5. 2-terminal-processed microsomal protein to mitochondria: A novel pathway for the biogenesis of hepatic mitochondrial P450MT2
6. Physiological role of the N-terminal processed P4501A1 targeted to mitochondria in erythromycin metabolism and reversal of erythromycin-mediated inhibition of mitochondrial protein synthesis
7. The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: Functional and localization studies
8. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions
9. Cytochrome P450 2C is an EDHF synthase in coronary arteries
10. Transfection of an active cytochrome P450 arachidonic acid epoxygenase indicates that 14,15-epoxyeicosatriennoic acid functions as an intracellular second messenger in response to epidermal growth factor
11. Physiological and pathophysiological regulation of cytochrome P450
12. The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450
13. Cytochrome P450IA expression in adult and fetal human liver
14. Immunohistochemical study of cytochrome P450 2C and 3A in human non-neoplastic and neoplastic tissues
15. Small intestinal cytochromes P450
16. Expression and localization of CYP3A4 and CYP3A5 in human lung
17. Cytochrome P450 3A proteins are expressed in B lymphocytes but not in T lymphocytes
18. Cytochrome-P450-dependent biotransformation of xenobiotics in human and rodent embryonic tissues
19. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53
20. Genetic epidemiology of environmental toxicity and cancer susceptibility: Human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues
21. Genetic polymorphisms and the risk of cancer: A review of the literature
22. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens
23. Regulation and expression of four cytochrome P-450 isoenzymes, NADPH-cytochrome P-450 reductase, the glutathione transferases B and C and microsomal epoxide hydrolase in preneoplastic and neoplastic lesions in rat liver
24. Development of cytochrome P-450-altered preneoplastic and neoplastic lesions during nitrosamine-induced hepatocarcinogenesis in the rat
25. A common biochemical pattern in preneoplastic hepatocyte nodules generated in four different models in the rat
26. Heme enzyme patterns in rat liver nodules and tumors
27. Xenobiotic metabolizing enzymes in genetically and chemically initiated mouse liver tumors
28. Immunohistochemically demonstrated altered expression of cytochrome P-450 molecular forms and epoxide hydrolase in N-ethyl-N-hydroxyethylnitrosamine-induced rat kidney and liver lesions
29. Identification of a new P450 subfamily, CYP4F1, expressed in rat hepatic tumours
30. Expression of cytochrome P450 2A5 in preneoplastic and neoplastic mouse liver lesions
31. Aryl hydrocarbon hydroxylase activity in mouse, rat, and human mammary tumors
32. Is aryl hydrocarbon hydroxylase activity a new prognostic indicator for breast cancer?
33. Expression of cytochrome P450IA in breast cancer
34. Expression of xenobiotic metabolising enzymes in breast cancer
35. Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue
36. Expression of cytochromes P450 in human breast tissue and tumors
37. Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues
38. Expression of cytochrome P450 CYP1B1 in breast cancer
39. Tumor-specific expression of cytochrome P450 CYP1B1
40. Immunohistochemical localisation of cytochrome P450 CYP1BI in breast cancer with monoclonal antibodies specific for CYP1B1
41. 17 Beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1
42. 4-hydroxylation of estrogens as markers of human mammary tumors
43. Implications for therapy of drug-metabolising enzymes in human colon cancer
44. Expression of drug-metabolizing enzymes and P-170 glycoprotein in colorectal carcinoma and normal mucosa
45. Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolizing enzyme systems
46. Xenobiotic metabolising enzyme expression in colonic neoplasia
47. Inter-individual differences in oxidative benzo(a)pyrene metabolism by normal and tumorous surgical lung specimens from 105 lung cancer patients
48. Expression of CYP1A1 gene in patients with lung cancer: Evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas
49. Main drug- and carcinogen-metabolizing enzyme systems in human non-small cell lung cancer and peri-tumoral tissues
50. Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue
51. Expression of cytochrome P450 3A enzymes in human lung: A combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours
52. Quantification of CYP2B7, CYP4B1, and CYPOR messenger RNAs in normal human lung and lung tumors
53. Hepatic drug-metabolizing enzymes in primary and secondary tumors of human liver
54. The expression of cytochrome P450, epoxide hydrolase and glutathione S-transferase in hepatocellular carcinoma
55. Differential expression drug metabolizing enzymes in primary and secondary liver neoplasm: Immunohistochemical characterization of cytochrome P4503A and glutathione-S-transferase
56. Expression of xenobiotic-metabolizing enzymes by primary and secondary tumors in man
57. Cytochrome P450 expression in oesophageal cancer
58. Expression of cytochrome P450s and glutathione S-transferases in human esophagus with squamous-cell carcinomas
59. Enhanced expression of cytochrome P450 in stomach cancer
60. The immunohistochemical localisation of drug metabolising enzymes in prostate cancer
61. Expression of xenobiotic metabolising enzymes in tumours of the urinary bladder
62. Principal xenobiotic-metabolizing enzyme systems in human head and neck squamous cell carcinoma
63. Transcriptional regulation of the human CYP1B1 gene: Evidence for involvement of an aryl hydrocarbon receptor response element in constitutive expression
64. Systematic variation in gene expression patterns in human cancer cell lines
65. Regulation of cytochrome P450 gene expression in human colon and breast tumour xenografts
66. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug
67. Cytochrome P-450 enzymes as targets for chemoprevention against chemical carcinogenesis and toxicity: Opportunities and limitations